A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

To join this study, you would need to be an adult, 18 years or older, diagnosed with non-small cell lung cancer. Your cancer must have been at a specific stage (Stage II, IIIA, or IIIB with lymph node involvement) and considered suitable for surgery by your doctor. Importantly, you would have already had surgery for your lung cancer, and doctors would have confirmed that some cancer cells remained after the operation, meaning you didn't have a "complete response".

Other important points include that your specific type of lung cancer shouldn't require certain targeted therapies (like those for EGFR or ALK gene changes) as the main treatment. You must also be well enough to receive certain chemotherapy drugs and pembrolizumab before your surgery, and any side effects from previous treatments need to have mostly cleared up. Your doctors would also need to confirm that there's no visible cancer remaining after your surgery based on scans.

Finally, there are some health conditions that might prevent you from joining, such as uncontrolled HIV or certain types of hepatitis, unless these conditions are well managed with treatment. The study team will review all your medical information carefully to see if this study is the right fit for you.

The detailed steps for participating in this study would be explained fully by the study team if you are eligible. Generally, once you are identified as potentially suitable after your lung cancer surgery, you would undergo several tests and scans to confirm your eligibility. If you meet all the requirements, you would then be assigned to receive either the combination of sacituzumab tirumotecan and pembrolizumab, or pembrolizumab alone.

You would receive these treatments over a period, likely through injections or infusions, and have regular check-ups, blood tests, and scans to monitor your health and how the treatment is working. There would also be follow-up appointments after your treatment period ends to continue checking on your health and cancer status. The total duration of the study, including treatment and follow-up, would be clearly explained by the researchers.